Loading...
45 antiandrogen COVID-19 controlled studies, 16 RCTs
https://c19early.com/aameta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani 77%
0.23 [0.08-0.66]
recov. time
8 (n)
262 (n)
Improvement, RR [CI] Treatment Control Cadegiani 83%
0.17 [0.06-0.51]
recov. time
8 (n)
262 (n)
Cadegiani 38%
0.62 [0.42-0.91]
viral time
8 (n)
262 (n)
McCoy (DB RCT) 80%
0.20 [0.01-4.13]
death
0/134
2/134
censored, see notes McCoy (DB RCT) 97%
0.03 [0.00-0.47]
ventilation
0/134
17/134
censored, see notes McCoy (DB RCT) 91%
0.09 [0.03-0.27]
hosp.
3/134
35/134
censored, see notes Cadegiani (DB RCT) 62%
0.38 [0.18-0.82]
no recov.
7/44
18/43
Cadegiani (DB RCT) 44%
0.56 [0.40-0.79]
recov. time
44 (n)
43 (n)
Cadegiani (DB RCT) 40%
0.60 [0.44-0.81]
recov. time
44 (n)
43 (n)
Cadegiani (DB RCT) 63%
0.37 [0.02-8.85]
death
0/75
1/102
Cadegiani (DB RCT) 90%
0.10 [0.01-1.84]
ventilation
0/75
5/102
Cadegiani (DB RCT) 86%
0.14 [0.03-0.60]
hosp.
2/75
19/102
Kintor (DB RCT) 67%
0.33 [0.01-8.16]
death
0/365
1/365
Kintor (DB RCT) 50%
0.50 [0.15-1.65]
hosp.
4/365
8/365
Kintor (DB RCT) 67%
0.33 [0.01-8.16]
death
0/360
1/361
Kintor (DB RCT) 71%
0.29 [0.06-1.37]
hosp.
2/360
7/361
Kintor (DB RCT) 67%
0.33 [0.01-8.16]
death
0/346
1/347
Kintor (DB RCT) 92%
0.08 [0.00-1.36]
hosp.
0/346
6/347
Kintor (DB RCT) 74%
0.26 [0.13-0.51]
viral+
n/a
n/a
Hunt 39%
0.61 [0.51-0.73]
death
167/1,788
1,445/24,720
Vicenzi 93%
0.07 [0.04-0.53]
death
30 (n)
39 (n)
OT1
Vicenzi 81%
0.19 [0.07-0.53]
death/int.
30 (n)
39 (n)
OT1
Goren 81%
0.19 [0.03-1.28]
ICU
1/12
17/36
Goren 86%
0.14 [0.02-0.94]
ICU
1/12
38/65
Goren -50%
1.50 [0.15-15.1]
death
1/12
2/36
Goren -35%
1.35 [0.17-11.1]
death
1/12
4/65
Mareev (RCT) 11%
0.89 [0.65-1.22]
no recov.
33 (n)
33 (n)
CT2
Mareev (RCT) 39%
0.61 [0.14-0.97]
no disch.
14/24
20/21
CT2
Mareev (RCT) 8%
0.92 [0.77-1.09]
hosp. time
33 (n)
33 (n)
CT2
Mareev (RCT) 87%
0.13 [0.01-2.25]
viral+
0/17
3/13
CT2
Zarehoseinz.. (RCT) 75%
0.25 [0.03-2.14]
death
1/40
4/40
Zarehoseinz.. (RCT) 0%
1.00 [0.06-15.4]
ICU
1/40
1/40
Ghandehari (RCT) -22%
1.22 [0.08-18.2]
death
1/18
1/22
Ghandehari (RCT) 85%
0.15 [0.01-2.82]
ventilation
0/18
3/22
Ghandehari (RCT) 76%
0.24 [0.03-1.91]
progression
1/18
5/22
Ghandehari (RCT) 39%
0.61 [0.18-2.11]
progression
3/18
6/22
Ersoy (ICU) 46%
0.54 [0.36-0.81]
death
14/30
26/30
ICU patients
Welén (RCT) 80%
0.20 [0.01-4.65]
death
0/29
1/10
Welén (RCT) 31%
0.69 [0.07-6.81]
ventilation
2/29
1/10
Welén (RCT) -133%
2.33 [1.06-5.00]
no disch.
29 (n)
10 (n)
Welén (RCT) -50%
1.50 [1.10-2.04]
hosp. time
29 (n)
10 (n)
Cadegiani (DB RCT) 78%
0.22 [0.16-0.30]
death
45/423
171/355
Cadegiani (DB RCT) 79%
0.21 [0.15-0.30]
death
34/423
138/355
Cadegiani (DB RCT) 45%
0.55 [0.49-0.62]
no recov.
423 (n)
355 (n)
Cadegiani (DB RCT) 55%
0.45 [0.39-0.52]
no recov.
423 (n)
355 (n)
Cadegiani (DB RCT) 33%
0.67 [0.54-0.82]
hosp. time
423 (n)
355 (n)
Davarpanah 78%
0.22 [0.08-0.55]
hosp.
6/103
23/103
CT2
Davarpanah 64%
0.36 [0.21-0.60]
recov. time
103 (n)
103 (n)
CT2
Kotfis (RCT) 17%
0.83 [0.25-2.74]
death
4/24
5/25
Kotfis (RCT) 11%
0.89 [0.35-2.28]
ICU
6/24
7/25
Kotfis (RCT) 30%
0.70 [0.24-2.01]
TFS
24 (n)
25 (n)
Abbasi (SB RCT) 55%
0.45 [0.18-1.13]
death
5/51
19/87
Abbasi (SB RCT) 34%
0.66 [0.30-1.48]
ventilation
7/51
18/87
Abbasi (SB RCT) 19%
0.81 [0.42-1.59]
ICU
10/51
21/87
Abbasi (SB RCT) 47%
0.53 [0.39-0.72]
no recov.
51 (n)
87 (n)
Gomaa (DB RCT) 91%
0.09 [0.01-1.56]
death
0/25
5/25
CT2
Gomaa (DB RCT) 91%
0.09 [0.01-1.56]
ventilation
0/25
5/25
CT2
Gomaa (DB RCT) 44%
0.56 [0.40-0.79]
recov. time
25 (n)
25 (n)
CT2
Gomaa (DB RCT) 33%
0.67 [0.52-0.85]
no recov.
25 (n)
25 (n)
CT2
Hsieh 88%
0.12 [0.01-2.22]
death
0/117
4/143
CT2
Hsieh 51%
0.49 [0.10-2.47]
ventilation
2/117
5/143
CT2
Hsieh 30%
0.70 [0.21-2.33]
ICU
4/117
7/143
CT2
Hsieh 88%
0.12 [0.01-2.22]
no recov.
0/117
4/143
CT2
Hsieh 36%
0.64 [0.51-0.80]
viral load
117 (n)
143 (n)
CT2
Nickols (DB RCT) 18%
0.82 [0.32-1.82]
death
11/62
7/34
Nickols (DB RCT) -19%
1.19 [0.50-2.84]
ventilation
13/62
6/34
Nickols (DB RCT) -17%
1.17 [0.50-2.28]
no recov.
15/62
7/34
Nickols (DB RCT) -20%
1.20 [0.02-92.1]
hosp. time
62 (n)
34 (n)
Gordon (DB RCT) 82%
0.18 [0.03-0.94]
death
n/a
n/a
Gordon (DB RCT) 76%
0.24 [0.03-1.63]
ventilation time
n/a
n/a
Gordon (DB RCT) 73%
0.27 [0.09-0.86]
ICU
n/a
n/a
Wadhwa (RCT) 72%
0.28 [0.09-0.85]
progression
4/74
9/46
Wadhwa (RCT) 49%
0.51 [0.27-0.95]
no disch.
13/74
16/46
Wadhwa (RCT) 18%
0.82 [0.67-1.00]
recov. time
74 (n)
46 (n)
Barnette (DB RCT) 55%
0.45 [0.27-0.74]
death
19/94
23/51
Barnette (DB RCT) 49%
0.51 [0.33-0.76]
ventilation time
98 (n)
52 (n)
Barnette (DB RCT) 44%
0.56 [0.40-0.80]
ICU
98 (n)
52 (n)
Barnette (DB RCT) 26%
0.74 [0.57-0.97]
hosp. time
98 (n)
52 (n)
Montopoli 95%
0.05 [0.00-12.3]
death
0/5,273
18/37,161
Montopoli 75%
0.25 [0.09-0.76]
severe case
1/5,273
31/37,161
Montopoli 75%
0.25 [0.09-0.65]
cases
4/5,273
114/37,161
Holt -129%
2.29 [1.59-3.32]
death/ICU
16/31
148/658
Koskinen 46%
0.54 [0.06-5.16]
death
1/134
3/218
Koskinen 46%
0.54 [0.06-5.16]
death/ICU
1/134
3/218
Koskinen 11%
0.89 [0.34-2.34]
cases
6/134
11/218
Patel 55%
0.45 [0.11-1.47]
death
4/22
10/36
Patel 69%
0.31 [0.05-1.81]
ventilation
22 (n)
36 (n)
Patel 77%
0.23 [0.06-0.79]
hosp.
22 (n)
36 (n)
Bennani 95%
0.05 [0.00-2063]
death
0/4
18/114
Bennani -119%
2.19 [0.37-12.9]
ICU
1/4
13/114
Bennani 25%
0.75 [0.28-2.02]
hosp.
2/4
76/114
Bennani 8%
0.92 [0.16-5.15]
severe case
1/4
31/114
Lazzeri -23%
1.23 [0.81-1.87]
death/ICU
Kwon 21%
0.79 [0.10-6.40]
death
1/799
7/4,412
Kwon -18%
1.18 [0.70-1.96]
cases
18/799
79/4,412
Klein -124%
2.24 [0.86-5.85]
death
6/304
13/1,475
Klein 7%
0.93 [0.55-1.56]
cases
17/304
85/1,475
Jeon 77%
0.23 [0.08-0.64]
cases
case control
Shaw (PSM) 6%
0.94 [0.90-0.98]
cases
47 (n)
97 (n)
Israel 38%
0.62 [0.41-0.91]
hosp.
case control
Jiménez-Alcaide 33%
0.67 [0.26-1.74]
death
3/11
17/50
Jiménez-Alcaide -8%
1.08 [0.54-1.83]
progression
11 (n)
50 (n)
Jiménez-Alcaide -68%
1.68 [0.90-3.16]
cases
11/156
50/1,193
Kazan -229%
3.29 [0.61-17.7]
hosp.
4/138
2/227
Kazan 29%
0.71 [0.39-1.32]
cases
13/138
30/227
Schmidt (PSM) 20%
0.80 [0.46-1.34]
death
25/169
44/308
Schmidt (PSM) 2%
0.98 [0.61-1.56]
severe case
169 (n)
308 (n)
Duarte 11%
0.89 [0.59-1.11]
death
100/156
32/43
Welén 2%
0.98 [0.61-1.59]
death
21/358
167/4,980
Welén 11%
0.89 [0.54-1.46]
death
20/334
167/4,980
Welén -151%
2.51 [1.52-4.16]
death
24/152
167/4,980
Welén -28%
1.28 [0.82-1.99]
ICU
24/358
216/4,980
Welén 13%
0.87 [0.51-1.48]
ICU
16/334
216/4,980
Welén 21%
0.79 [0.34-1.86]
ICU
6/152
216/4,980
Welén -23%
1.23 [0.96-1.56]
hosp.
126/358
1,108/4,980
Welén -24%
1.24 [0.97-1.59]
hosp.
126/334
1,108/4,980
Welén -40%
1.40 [0.98-1.99]
hosp.
66/152
1,108/4,980
Gedeborg -25%
1.25 [0.95-1.65]
death
case control
Lyon 17%
0.83 [0.42-1.63]
death
15/944
19/994
Lyon 7%
0.93 [0.86-1.00]
cases
399/944
446/994
Lee (PSW) 21%
0.79 [0.62-0.97]
severe case
76/295
727/2,427
Lee (PSW) 11%
0.89 [0.82-0.95]
cases
295/3,057
2,427/36,096
MacFadden 7%
0.93 [0.88-0.98]
cases
n/a
n/a
Shah -16%
1.16 [0.68-1.98]
death
148 (n)
317 (n)
Shah 19%
0.81 [0.25-2.66]
ventilation
148 (n)
317 (n)
Shah -3%
1.03 [0.57-1.87]
severe case
148 (n)
317 (n)
Shah 4%
0.96 [0.52-1.77]
hosp.
148 (n)
317 (n)
Cousins (PSM) 69%
0.31 [0.07-1.00]
ventilation
794 (n)
794 (n)
Cousins (PSM) 58%
0.42 [0.22-0.78]
ICU
794 (n)
794 (n)
antiandrogen COVID-19 outcomes c19early.com/aa Oct 2022
1 OT: comparison with other treatment 2 CT: study uses combined treatment Favors antiandrogen
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
